With the inherent value medications provide in the greater health care system, Jennifer Hammons, PharmD, DrPH, argues that rural pharmacies deserve the proper recognition.
News|Articles|October 10, 2025
The Most Favored Nation Drug Policy’s Impact on Access, Pharmaceutical Innovation
Author(s)Brian Nowosielski
In part 2 of a roundtable on the Most Favored Nation Executive Order for prescription drugs, experts gathered to discuss recent developments and how they’ll impact the policy’s future.
Advertisement
Advertisement
Amid incoming pharmaceutical tariffs and an unprecedented deal between Pfizer and the White House, pharmacy industry and drug market experts gathered for part 2 of a roundtable discussion exploring further developments on President Donald Trump’s Most Favored Nation (MFN) Drug Policy Executive Order.
Related to this article
This episode offers a detailed look into the FDA’s recent PCAC meeting and what the future of peptide compounding could lead to for pharmacy professionals.
As midterm elections approach, the pharmacy industry is backing one of its most meaningful bills yet while the current congressional session wanes.
Chad Worz, PharmD, BCGP, FASCP, explains why the Main Street Pharmacy Access Act's reimbursement provisions are key to unlocking pharmacy's clinical future.
As a government price-setting formula, the same arithmetic has produced the opposite result.
Orforglipron lowered A1C and body weight more than oral semaglutide 25 mg at 52 weeks, but the estimate comes from an indirect comparison.
Brian Smith, PharmD, explains how direct-to-consumer GLP-1 pathways broaden initial access but endanger long-term patient adherence.
Pharmacists face burnout and financial strain as PBMs take big cuts, prompting urgent calls for reform to protect patient care and community pharmacies.
Advertisement
Advertisement